Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Separation of immunomodulatory and cholesterol-lowering activities of heterocyclic azaspiranes.

Albrightson CR, Bugelski PJ, Berkhout TA, Jackson B, Kerns WD, Organ AJ, Badger AM.

J Pharmacol Exp Ther. 1995 Feb;272(2):689-98.

PMID:
7853183
2.
3.

Biochemical and functional analysis of rat bronchoalveolar macrophages containing chemically induced phospholipid inclusions.

Waites CR, Bugelski PJ, Badger AM.

Toxicol Appl Pharmacol. 1995 Feb;130(2):316-21.

PMID:
7871542
4.
5.

Antiarthritic and suppressor cell inducing activity of azaspiranes: structure-function relationships of a novel class of immunomodulatory agents.

Badger AM, Schwartz DA, Picker DH, Dorman JW, Bradley FC, Cheeseman EN, DiMartino MJ, Hanna N, Mirabelli CK.

J Med Chem. 1990 Nov;33(11):2963-70.

PMID:
2146392
7.

Effects of SK&F 105685, a novel anti-arthritic agent, on immune function in the dog.

Kaplan JM, Badger AM, Ruggieri EV, Swift BA, Bugelski PJ.

Int J Immunopharmacol. 1993 Feb;15(2):113-23.

PMID:
8468115
8.

Pharmacological profile of F 12511, (S)-2',3', 5'-trimethyl-4'-hydroxy-alpha-dodecylthioacetanilide a powerful and systemic acylcoenzyme A: cholesterol acyltransferase inhibitor.

Junquero D, Oms P, Carilla-Durand E, Autin J, Tarayre J, Degryse A, Patoiseau J, Colpaert FC, Delhon A.

Biochem Pharmacol. 2001 Jan 1;61(1):97-108.

PMID:
11137714
9.

Inhibition of animal models of autoimmune disease and the induction of non-specific suppressor cells by SK&F 105685 and related azaspiranes.

Badger AM, Dimartino MJ, Talmadge JE, Picker DH, Schwartz DA, Dorman JW, Mirabelli CK, Hanna N.

Int J Immunopharmacol. 1989;11(7):839-46.

PMID:
2532178
10.

Pharmacological properties of YM17E, an acyl-CoA:cholesterol acyltransferase inhibitor, and diarrheal effect in beagle dogs.

Kashiwa M, Masuyama Y, Miyauchi H, Uchida T, Naganuma S, Kakuta H, Terada M, Kiriyama T, Matsuda K, Ito N, Iizumi Y, Takenaka T.

Jpn J Pharmacol. 1997 Jan;73(1):41-50.

11.
12.

Induction of non-specific suppressor cells in normal Lewis rats by a novel azaspirane SK&F 105685.

Badger AM, King AG, Talmadge JE, Schwartz DA, Picker DH, Mirabelli CK, Hanna N.

J Autoimmun. 1990 Aug;3(4):485-500.

PMID:
2145847
13.

Apomine, a novel hypocholesterolemic agent, accelerates degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and stimulates low density lipoprotein receptor activity.

Roitelman J, Masson D, Avner R, Ammon-Zufferey C, Perez A, Guyon-Gellin Y, Bentzen CL, Niesor EJ.

J Biol Chem. 2004 Feb 20;279(8):6465-73. Epub 2003 Nov 19.

14.

Induction of suppressor cell activity in vivo and suppression of lymphoproliferative responses in vitro by SK&F 105.685 in the dog.

Thiem PA, Kaplan JM, Bugelski PJ, Ruggieri EV, Badger AM.

Immunopharmacology. 1992 Mar-Apr;23(2):67-74.

PMID:
1534791
15.

An alternative mechanism for the inhibition of cholesterol biosynthesis in HepG2 cells by N-[(1,5,9)-trimethyldecyl]-4 alpha,10-dimethyl-8-aza-trans-decal-3 beta-ol (MDL 28,815).

Van Sickle WA, Wilson PK, Wannamaker MW, Cooper JR, Flanagan MA, McCarthy JR, Bey P, Jackson RL.

J Pharmacol Exp Ther. 1993 Dec;267(3):1243-9.

PMID:
8263786
16.
17.

Atiprimod (SK&F 106615), a novel macrophage targeting agent, enhances alveolar macrophage candidacidal activity and is not immunosuppressive in Candida-infected mice.

Badger AM, Handler JA, Genell CA, Herzyk D, Gore E, Polsky R, Webb L, Bugelski PJ.

Int J Immunopharmacol. 1999 Mar;21(3):161-76.

PMID:
10348366
18.

Divergent pharmacologic activities of PD 132301-2 and CL 277,082, urea inhibitors of acyl-CoA:cholesterol acyltransferase.

Krause BR, Black A, Bousley R, Essenburg A, Cornicelli J, Holmes A, Homan R, Kieft K, Sekerke C, Shaw-Hes MK, et al.

J Pharmacol Exp Ther. 1993 Nov;267(2):734-43.

PMID:
8246149
20.

Pharmacological profile of SMP-797, a novel acyl-coenzyme a: cholesterol acyltransferase inhibitor with inducible effect on the expression of low-density lipoprotein receptor.

Ioriya K, Kino K, Horisawa S, Nishimura T, Muraoka M, Noguchi T, Ohashi N.

J Cardiovasc Pharmacol. 2006 Feb;47(2):322-9.

PMID:
16495773

Supplemental Content

Support Center